ARROWHEAD PHARMACEUTICALS, INC. annual report, FY2015

Business context and reporting period

Arrowhead Research Corporation (now identified in the request as Arrowhead Pharmaceuticals) filed this Form 10-K for the fiscal year ended September 30, 2015; it is not a quarterly report, although the metadata labels the period “2015 Q4.” The company was a clinical-stage RNA interference (RNAi) drug developer with no approved products. Its lead programs were ARC-520 for chronic hepatitis B and ARC-AAT for liver disease associated with alpha-1 antitrypsin deficiency.

In March 2015, Arrowhead acquired Novartis RNAi assets for $35 million: $10 million cash and $25 million in stock, plus potential future royalties and milestone payments. The acquired assets included patents, a license, and three preclinical candidates.

Financial performance and position

• Revenue remained immaterial relative to spending and was primarily from licensed technology and collaboration activity; the filing reports no product sales.
• Operating cash used was $65.7 million, versus $35.4 million in FY 2014. Investing activities provided $14.1 million, primarily from maturities of marketable securities, after $10.0 million cash paid for Novartis assets. Financing provided $0.3 million.
• Cash plus investments totaled approximately $98.8 million at year-end. Management said available resources and its operating plan were expected to fund operations for at least the next 12 months.
• No conventional debt was reported in the contractual-obligations table. Capital lease obligations were $0.76 million; other long-term liabilities were $6.2 million, including $5.9 million of contingent consideration.
• Purchase commitments were approximately $49.3 million, of which $35.5 million was expected in FY 2016. Operating lease commitments totaled $2.3 million.
• No meaningful operating margin comparison is useful given the negligible revenue and substantial development-stage losses.

Material changes versus the prior comparable period

• R&D expense more than doubled, increasing 104%, mainly because of ARC-520 clinical-supply manufacturing, toxicology, and clinical-trial costs. Clinical-trial expense rose to $13.3 million from $2.6 million; drug-manufacturing expense rose to $21.4 million from $9.1 million.
• FY 2015 included a $10.1 million acquired in-process R&D charge for the Novartis preclinical candidates. The rest of the acquisition consideration was principally recorded as intangible assets.
• Net loss increased from $58.7 million to $91.9 million, while cash and investments declined by $78.5 million in aggregate. FY 2014 cash had benefited from approximately $172.6 million in equity-financing proceeds; FY 2015 financing proceeds were minimal.
• Other income was $4.0 million in FY 2015, compared with $5.4 million of other expense in FY 2014, chiefly reflecting a $2.9 million noncash gain from changes in derivative fair value versus a $6.0 million loss in FY 2014.
• Common shares outstanding increased from 54.7 million to 59.5 million, including 3.32 million shares issued as part of the Novartis acquisition.

Outlook, commentary, risks, and unusual items

• Management expected continued significant R&D spending and stated clinical-trial expense would increase further in FY 2016 as enrollment expanded. It gave no revenue or earnings guidance.
• ARC-520 was in multiple Phase 2b studies. In Phase 2a, the company reported HBsAg reductions up to 1.9 logs in certain patients; effects varied by patient group, and the company noted evidence that integrated HBV DNA may contribute to HBsAg production. These findings do not establish clinical benefit or a functional cure.
• ARC-AAT was in a Phase 1a/1b study, with patient dosing underway; the FDA had granted orphan drug designation. ARC-521, ARC-F12, ARC-HIF2, and ARC-LPA remained preclinical or earlier-stage programs.
• Management emphasized that RNAi delivery and the drug candidates remained experimental. Key risks include clinical failure or delay, safety findings on repeat dosing, manufacturing scale-up and third-party reliance, regulatory hurdles, competition, intellectual-property disputes, and the need for future financing. The company had incurred losses since inception and expected losses to continue.
• Litigation included securities class-action and derivative suits related to statements about HBV research, and a separate Rice University dispute involving a former subsidiary’s license. The company said it intended to defend the matters and recorded no liability, stating it did not expect a material financial-statement effect.
• FY 2015 included $10.2 million of noncash stock-based compensation and $1.9 million of noncash contingent-consideration fair-value expense. The Novartis asset purchase was $35 million in total consideration, including stock and potential contingent payments.

Most important facts for investors to verify

• Review subsequent ARC-520 trial results, safety—particularly with multiple dosing—and whether antigen reductions translate into meaningful patient outcomes.
• Track ARC-AAT patient data, dose escalation, safety, and evidence of effects on liver disease, not only circulating AAT levels.
• Assess cash consumption against the $49.3 million in purchase commitments and management’s stated 12-month liquidity expectation; confirm later financing needs and dilution.
• Examine Novartis-related royalty, milestone, and right-of-first-negotiation terms, as well as the assumptions behind contingent-consideration valuations.
• Follow the status and potential financial impact of the disclosed litigation, and confirm whether any resolution or new accrual is reported subsequently.
• Reconcile share-count changes and potential dilution from preferred stock, options, restricted stock units, and warrants.